Pfizer to acquire Biohaven Pharma for $11.6 billion
Posted on11 May 2022
Comments0
Pfizer entered into a definitive agreement under which Pfizer will acquire Biohaven for 11.6 billion $. Biohen is the maker of Nurtec... Read More
Aurobindo Pharma acquires Veritaz Healthcare
Aurobindo Pharma Ltd has announced the acquisition of the domestic formulation business of Veritaz Healthcare for a consideration of Rs. 171 crore... Read More
Is HEOR and Market Access is same?
HEOR and market access are the two separate domain or functional area within pharmaceutical organization. But they work for the same or... Read More
Lynk Pharma, Simcere licensing deal for development of novel JAK1 inhibitor LNK01001 in China
Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.... Read More
Insight on AstraZeneca’s global R&D Postdoctoral Challenge initiative
AstraZeneca launched a global R&D Postdoctoral Challenge to help accelerate ideas to transform the treatment of some of the world’s most complex... Read More
Case Study: Pfizer’s Arena acquisition – A $6.7B deal
Pfizer will acquire Arena Pharmaceuticals for $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. Why Pfizer acquired Arena?... Read More
Keros Therapeutics Strategic deal with Hansoh Pharma for Rights to KER-050 in China
Keros Therapeutics Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological... Read More
Case Insight: Natco acquires Dash Pharmaceuticals
Posted on17 Dec 2021
Comments0
NATCO Pharma, through its affiliates, is proposing to enter into an agreement to acquire Dash Pharmaceuticals LLC subject to satisfactory completion of... Read More
Aqilion buys rights to Phase-I ready anti-inflammatory program from LEO Pharma
Swedish life science company Aqilion has acquired all rights to Regulus, a Phase I-ready anti-inflammatory program, from Denmark-headquartered dermatology specialist LEO Pharma,... Read More
SPARC entered into a licensing agreement with Biomodifying
Sun Pharma Advanced Research Company (SPARC) has entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique... Read More